Tara Graff, DO

Articles by Tara Graff, DO

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) may include issues related to access, cost, and patient adherence, and highlight the need for ongoing research and collaboration to optimize BTKi use and improve patient outcomes in both diseases.

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address unmet clinical needs in MCL therapy.

Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for treatment-naive patients, with a focus on emerging Bruton tyrosine kinase inhibitor (BTKi) regimens such as acalabrutinib plus venetoclax, pirtobrutinib plus venetoclax, and zanubrutinib combinations.

Latest Updated Articles



    Brand Logo

    259 Prospect Plains Rd, Bldg H
    Monroe, NJ 08831

    609-716-7777

    © 2025 MJH Life Sciences®

    All rights reserved.

    Secondary Brand Logo